ASH 2023 | Mitigating cardiological toxicities associated with BTKi in B-cell malignancies
Alessandra Ferrajoli, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses cardiological toxicities associated with BTK inhibitors (BTKi) when treating B-cell malignancies. Emphasizing the crucial role of multi-disciplinary teams (MDT), including hematologists, oncologists, and cardiologists, she underscores the significance of collaborative efforts in minimizing patient risks through strategic pharmacological interventions. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Genetech, Janssen, AstraZeneca, Abbvie
Research Funding: GenMab, Beigene, AstraZeneca, Abbvie
